N-氨甲醯穀氨酸
化合物
N-氨甲醯穀氨酸(英語:Carglumic acid,商品名:Carbaglu等)是一種有機化合物,分子式C6H10N2O5,用於治療高氨血症[3][6][7]。
臨床資料 | |
---|---|
商品名 | Carbaglu, Ucedane |
其他名稱 | (S)-2-ureidopentanedioic acid |
AHFS/Drugs.com | Monograph |
核准狀況 | |
懷孕分級 |
|
給藥途徑 | By mouth |
ATC碼 | |
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
生物利用度 | 30% |
血漿蛋白結合率 | Undetermined |
藥物代謝 | Partial |
生物半衰期 | 4.3 to 9.5 hours |
排泄途徑 | Fecal (60%) and kidney (9%, unchanged) |
識別資訊 | |
| |
CAS號 | 1188-38-1 |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.116.323 |
化學資訊 | |
化學式 | C6H10N2O5 |
摩爾質量 | 190.16 g·mol−1 |
3D模型(JSmol) | |
| |
|
參考文獻
- ^ Prescription medicines: registration of new chemical entities in Australia, 2015. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023].
- ^ Health Canada New Drug Authorizations: 2015 Highlights. Health Canada. 4 May 2016 [7 April 2024].
- ^ 3.0 3.1 Carbaglu- carglumic acid tablet. DailyMed. [9 June 2021].
- ^ Carbaglu EPAR. European Medicines Agency (EMA). 17 September 2018 [9 June 2021].
- ^ Ucedane EPAR. European Medicines Agency (EMA). 17 September 2018 [9 June 2021].
- ^ Caldovic L, Morizono H, Daikhin Y, Nissim I, McCarter RJ, Yudkoff M, Tuchman M. Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate. J Pediatr. 2004, 145 (4): 552–4. PMID 15480384. doi:10.1016/j.jpeds.2004.06.047.
- ^ Elpeleg O, Shaag A, Ben-Shalom E, Schmid T, Bachmann C. N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy. Ann Neurol. 2002, 52 (6): 845–9. PMID 12447942. S2CID 24604774. doi:10.1002/ana.10406 .